MIBG scintiscanAdrenal medullary imaging; Meta-iodobenzylguanidine scintiscan; Pheochromocytoma - MIBG; Neuroblastoma - MIBG; Carcinoid MIBG
An MIBG scintiscan is a type of imaging test. It uses a radioactive substance (called a tracer). A scanner finds or confirms the presence of pheochromocytoma and neuroblastoma. These are types of tumors that affect nerve tissue.
Pheochromocytoma is a rare tumor of adrenal gland tissue. It results in the release of too much epinephrine and norepinephrine, hormones that contro...Read Article Now Book Mark Article
Neuroblastoma is a very rare type of cancerous tumor that develops from nerve tissue. It usually occurs in infants and children.Read Article Now Book Mark Article
How the Test is Performed
A radioisotope (MIBG, iodine-131-meta-iodobenzylguanidine, or iodine-123-meta-iodobenzylguanidine) is injected into a vein. This compound attaches to specific tumor cells.
You will have the scan later that day or the next day. For this part of the test, you lie on a table under the arm of the scanner. Your abdomen is scanned. You may need to return for repeated scans for 1 to 3 days. Each scan takes 1 to 2 hours.
Before or during the test, you may be given an iodine mixture. This prevents your thyroid gland from absorbing too much of the radioisotope.
How to Prepare for the Test
You will need to sign an informed consent form. You will be asked to wear a hospital gown or loose-fitting clothes. You will need to remove jewelry or metal objects before each scan. Many drugs interfere with the test. Ask your health care provider which of your regular medicines you may need to stop taking before the test.
How the Test will Feel
You will feel a sharp needle prick when the material is injected. The table may be cold or hard. You must lie still during the scan.
Why the Test is Performed
This test is done to help diagnose pheochromocytoma. It is done when an abdominal CT scan does not give a definite answer. It is also used to help diagnose neuroblastoma and can be used for carcinoid tumors.
Abdominal CT scan
An abdominal CT scan is an imaging method. This test uses x-rays to create cross-sectional pictures of the belly area. CT stands for computed tomog...Read Article Now Book Mark Article
There are no signs of a tumor.
What Abnormal Results Mean
Abnormal results may indicate:
There is some exposure to radiation from the radioisotope. The radiation from this radioisotope is higher than from many others. You may need to take extra precautions for a few days after the test. Your provider will tell you what actions to take.
Before or during the test, you may be given an iodine solution. This will keep your thyroid gland from absorbing too much iodine. Usually people take potassium iodide for 1 day prior and 6 days after. This blocks the thyroid from taking up the MIBG.
This test should NOT be done on pregnant women. The radiation can pose danger to the unborn baby.
Bleeker G, Tytgat GA, Adam JA, et al. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev. 2015;(9):CDC009263. PMID: 26417712 www.ncbi.nlm.nih.gov/pubmed/26417712.
Hutton BF, Segerman D, Miles KA. Radionuclide and hybrid imaging. In: Adam A, Dixon AK, Gillard JH, Schaefer-Prokop CM, eds. Grainger & Allison's Diagnostic Radiology. 6th ed. New York, NY: Elsevier Churchill Livingstone; 2015:chap 6.
Patel D, Nilubol N, Kebebew E. The management of pheochromocytoma. In: Cameron JL, Cameron AM, eds. Current Surgical Therapy. 12th ed. Philadelphia, PA: Elsevier; 2017:760-767.
Young WF. Adrenal medulla, catecholamines, and pheochromocytoma. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 228.
MIBG injection - illustration
During a MIBG scintiscan, the radioisotope MIBG is injected into a vein and then the abdomen is scanned. The scanner detects radiation from the radioisotope, MIBG, in order to locate or confirm pheochromocytoma, an adrenal gland tumor.
Review Date: 6/25/2018
Reviewed By: Jason Levy, MD, Northside Radiology Associates, Atlanta, GA. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.